WO1995031986A1 - Combination product of dichloroacetic acid and an nmda antagonist - Google Patents
Combination product of dichloroacetic acid and an nmda antagonist Download PDFInfo
- Publication number
- WO1995031986A1 WO1995031986A1 PCT/GB1995/001205 GB9501205W WO9531986A1 WO 1995031986 A1 WO1995031986 A1 WO 1995031986A1 GB 9501205 W GB9501205 W GB 9501205W WO 9531986 A1 WO9531986 A1 WO 9531986A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nmda receptor
- pharmaceutically acceptable
- receptor antagonist
- phenyl
- diphenyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
Definitions
- This invention relates to the combined use of a known compound with compounds of a known class in the treatment of neurodegenerative disorders, and to products comprising the known compound and compounds of the known class.
- DCA dichloroacetic acid
- DCA or a pharmaceutically acceptable salt thereof, in conjunction with an NMDA receptor antagonist, is particularly advantageous.
- a pharmaceutical s formulation comprising: i) DCA, or a pharmaceutically acceptable salt thereof; and ii) an NMDA receptor antagonist; in admixture with a pharmaceutically acceptable diluent or carrier.
- the combination of the components (i) and (ii) according to the invention may 0 have the advantage that it provides a pharmaceutical formulation which is less toxic, more efficacious, longer acting, has a broader range of activity, is more potent, produces fewer side effects, is synergistic, is more easily absorbed or has other more useful pharmacological properties than the components of the combination when used individually. Synergistic combinations are preferred.
- Pharmaceutically acceptable salts of DCA which may be mentioned include alkali and alkaline earth metal salts, for example sodium and calcium salts.
- NMDA receptor antagonists of particular interest are 2-amino-N-(l,2-diphenyl- l-methylethyl)-acetamide (disclosed in European Patent Application 279937), 1,2- diphenyl-2-propylamine (mentioned in European Patent Application 356035), (S)- ⁇ - o phenyl-2-pyridineethanamine (claimed in International Patent Application WO 93/20052 and the racemate of which is mentioned in European Patent Application 356035 under the alternative name of l-phenyl-2-(2-pyridinyl)-ethylamine and from which this enantiomer may be prepared by fractional crystallization), MK-801 (10,ll-dihydro-5- methyl-5H-dibenzo[a,d]cyclohepten-5,10-imine, US Patent 4,399, 141), cis-4- [phosphonomethyl]-2-piperidine carboxylic acid (also known as CGS 19755, Selfotel), N- (3-
- NMDA receptor antagonists of most particular interest are 2-amino-N-(l,2- diphenyl-l-methylethyl)-acetamide and (5)- ⁇ -phenyl-2-pyridineethanamine, or a pharmaceutically acceptable salt thereof, especially (S)- ⁇ -phenyl-2-pyridineethanamine, or a pharmaceutically acceptable salt thereof.
- NMDA receptor antagonist NMDA receptor antagonist
- two or more NMDA antagonists in combination.
- the ratio of components (i) and (ii) of the formulation will vary with the particular NMDA receptor antagonist and the specific purpose for which the formulation is intended. Nevertheless, this ratio will typically be in the range 50:1-1:2, preferably 20:1-1:1, especially 10:1-1:1 by weight of the active principle (e.g., in the case of a salt, of the pharmacologically active ion).
- NMDA receptor antagonists which are basic or capable of forming a cation of particular interest are 2-amino-N-(l,2-diphenyl-l-methylethyl)-acetamide, l,2-diphenyl-2- propylamine, (5)- ⁇ -phenyl-2-pyridineethanamine), MK-801, N-(3-ethylphenyl)-N-methyl- N'-l-naphthalenyl-guanidine and N-ethyl-l-phenyl-2-(3-pyrazine)ethanamine.
- NMDA receptor antagonists which are basic or capable of forming a cation of most particular interest are 2-amino-N-(l,2-diphenyl-l-methylethyl)-acetamide and (S)-a- phenyl-2-pyridineethanamine, especially (5)- ⁇ -phenyl-2-pyridineethanamine.
- a pharmaceutical formulation comprising a dichloroacetic acid salt of an NMDA receptor antagonist which is basic or capable of forming a cation in s admixture with a pharmaceutically acceptable diluent or carrier.
- the salt may be made by a metathetical process e.g. by reacting dichloroacetic acid with a suitable salt of the NMDA receptor antagonist.
- the reaction may be carried out in a solvent which is inert under reaction conditions.
- the solvent is preferably one in which the desired salt is soluble, e.g. water.
- the desired salt may be 0 isolated and purified by, for example, crystallisation or freeze drying.
- formulations and salts according to the invention are useful in the treatment of neurodegenerative disorders.
- neurodegenerative disorders include stroke, cerebral ischaemia, cerebral palsy, the effects of hypoglycaemia, epilepsy, AIDS-related s dementia, Alzheimer's disease, Huntington's chorea, Olivo-ponto-cerebellar atrophy, perinatal asphyxia, Parkinson's disease, anoxia, neuronal damage associated with substance abuse (for example, narcotics or cocaine), retinopathies, schizophrenia, ischaemic states after cardiac arrest or surgical operations, intoxication or injuries of the spinal cord and amyotrophic lateral sclerosis.
- neuronal loss or damage following head injury, brain trauma and sub-arachnoid haemorrhage.
- a pharmaceutical pack comprising: i) DCA, or a pharmaceutically acceptable salt thereof; and 5 ii) an NMDA receptor antagonist; as a combined preparation for simultaneous, separate or sequential administration in the treatment of a neurodegenerative disorder.
- simultaneous use administration of the two components in a single pharmaceutical formulation.
- simultaneous use is meant administration of the two components in separate pharmaceutical formulations, but with a short period of time between each administration, for example up to 5 minutes.
- separatate use is meant administration of the two components in separate pharmaceutical formulations, but with a relatively longer period of time between each administration, for example from 5 minutes to 12 hours.
- the components may be administered by any convenient route, for example parenterally, rectally, and orally.
- Pharmaceutical formulations comprising the components include solid dosage forms, for example tablets, pills, capsules, powders, granules, and suppositories for oral, parenteral or rectal administration; and liquid dosage forms, for example sterile parenteral solutions or suspensions, suitably flavoured syrups, flavoured emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil and peanut oil, and elixirs and similar pharmaceutical diluents or carriers.
- Solid compositions may be prepared by mixing the components with pharmaceutical carriers, for example conventional tabletting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate, gums and other diluents, for example water, to form a homogeneous preformulation composition in which the components are uniformly dispersed.
- pharmaceutical carriers for example conventional tabletting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate, gums and other diluents, for example water, to form a homogeneous preformulation composition in which the components are uniformly dispersed.
- the solid dosage forms may be coated or otherwise compounded to prolong the action of the composition.
- a method of treatment or prophylaxis of a neurodegenerative disorder which comprises the simultaneous, separate or sequential administration of: i) DCA, or a pharmaceutically acceptable salt thereof; and ii) an NMDA receptor antagonist; to a patient suffering from or at risk of suffering from such a disorder.
- a method of treatment or prophylaxis of a neurodegenerative disorder which comprises the administration of a dichloroacetic acid salt of an NMDA receptor antagonist which is basic or capable of forming a cation to a patient suffering from or at risk of suffering from such a disorder.
- an NMDA receptor antagonist in the manufacture of a medicament for simultaneous, separate or sequential administration in the treatment or prophylaxis of a neurodegenerative disorder.
- a dichloroacetic acid salt of an NMDA receptor antagonist which is basic or capable of forming a cation in the manufacture of s a medicament for the treatment or prophylaxis of a neurodegenerative disorder.
- DCA DCA, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for combination therapy by simultaneous, separate or sequential administration with an NMDA receptor antagonist for the treatment or prophylaxis of 0 a neurodegenerative disorder.
- an NMDA receptor antagonist in the manufacture of a medicament for combination therapy by simultaneous, separate or sequential administration with DCA, or a pharmaceutically acceptable salt thereof, for the treatment or prophylaxis of a s neurodegenerative disorder.
- the dosage administered will, of course, vary with the compounds employed, the mode of administration and the treatment desired. However, in general, satisfactory results are obtained when compounds of components (i) and (ii) are each administered at a daily dosage of from about O.lmg to about lOOmg o per kg of body weight, perhaps given in divided doses 1 to 4 times a day or in sustained release form.
- the total daily dose of DCA is in the range of from 50mg to 5,000mg, more preferably from lOOmg to 3,500mg and for an NMDA antagonist, from 5 mg to l,400mg, more preferably from lOmg to 500mg.
- DCA DCA, 3.5g/l and 2-amino-N-(l,2-diphenyl-l-methylethyl)-acetamide, 0.42g/l made up in 1 litre of isotonic saline at pH 7.4.
- DCA DCA, 3.5g/l and 2-amino-N-(l,2-diphenyl-l-methylethyl)-acetamide, 0.21g/l made up in 1 litre of isotonic saline at pH 7.4.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
According to the invention there is provided a pharmaceutical formulation comprising: i) dichloroacetic acid (DCA), or a pharmaceutically acceptable salt thereof; and ii) an NMDA receptor antagonist; in admixture with a pharmaceutically acceptable diluent or carrier. A particular example of the formulation includes the DCA salt of an NMDA receptor antagonist which is basic or capable of forming a cation. The formulation according to the invention is useful in the treatment of neurodegenerative disorders.
Description
Combination product of dlchloroacetlc add and a NMDA antagoni st
This invention relates to the combined use of a known compound with compounds of a known class in the treatment of neurodegenerative disorders, and to products comprising the known compound and compounds of the known class.
5 The use of dichloroacetic acid (DCA) in the treatment of brain injuiy following ischaemia has been described in US Patent 4,631,294 and by Chang et al (Journal of Cerebral Blood Flow and Metabolism, 12, 1030-1038, 1992). NMDA receptor antagonists have been indicated in the treatment of neurodegenerative disorders previously (see, for example, European Patent Application 356035 and Choi, D.W. o (1987) J Neuroscience, 7(2), 369-379).
Surprisingly, we have now found that the combined use of DCA, or a pharmaceutically acceptable salt thereof, in conjunction with an NMDA receptor antagonist, is particularly advantageous.
Thus, according to the present invention, there is provided a pharmaceutical s formulation comprising: i) DCA, or a pharmaceutically acceptable salt thereof; and ii) an NMDA receptor antagonist; in admixture with a pharmaceutically acceptable diluent or carrier.
The combination of the components (i) and (ii) according to the invention may 0 have the advantage that it provides a pharmaceutical formulation which is less toxic, more efficacious, longer acting, has a broader range of activity, is more potent, produces fewer side effects, is synergistic, is more easily absorbed or has other more useful pharmacological properties than the components of the combination when used individually. Synergistic combinations are preferred. s Pharmaceutically acceptable salts of DCA which may be mentioned include alkali and alkaline earth metal salts, for example sodium and calcium salts.
NMDA receptor antagonists of particular interest are 2-amino-N-(l,2-diphenyl- l-methylethyl)-acetamide (disclosed in European Patent Application 279937), 1,2- diphenyl-2-propylamine (mentioned in European Patent Application 356035), (S)-α- o phenyl-2-pyridineethanamine (claimed in International Patent Application WO 93/20052 and the racemate of which is mentioned in European Patent Application 356035 under the alternative name of l-phenyl-2-(2-pyridinyl)-ethylamine and from which this enantiomer may be prepared by fractional crystallization), MK-801 (10,ll-dihydro-5-
methyl-5H-dibenzo[a,d]cyclohepten-5,10-imine, US Patent 4,399, 141), cis-4- [phosphonomethyl]-2-piperidine carboxylic acid (also known as CGS 19755, Selfotel), N- (3-ethylphenyl)-N-methyl-N'-l-naphthalenyl-guanidine (also known as CNS-1102, Cerestat), N-ethyl-l-phenyl-2-(3-pyrazine)ethanamine (disclosed in International Patent Application WO 93/09095 under the name N-ethyl-lrphenyl-2-(2-pyrazine)ethanamine) or a pharmaceutically acceptable salt of any one thereof.
NMDA receptor antagonists of most particular interest are 2-amino-N-(l,2- diphenyl-l-methylethyl)-acetamide and (5)-α-phenyl-2-pyridineethanamine, or a pharmaceutically acceptable salt thereof, especially (S)-α-phenyl-2-pyridineethanamine, or a pharmaceutically acceptable salt thereof.
Although the use of one NMDA receptor antagonist is preferred, we envisage within the scope of the invention the use of two or more NMDA antagonists in combination.
The ratio of components (i) and (ii) of the formulation will vary with the particular NMDA receptor antagonist and the specific purpose for which the formulation is intended. Nevertheless, this ratio will typically be in the range 50:1-1:2, preferably 20:1-1:1, especially 10:1-1:1 by weight of the active principle (e.g., in the case of a salt, of the pharmacologically active ion).
Special combinations of components (i) and (ii) above which may be mentioned are the dichloroacetic acid salts of NMDA receptor antagonists which are basic or are capable of forming a cation. An example of such is the dichloroacetic acid salt of (S)-a- phenyl-2-pyridineethanamine.
Thus, as a further aspect of the invention, we provide a dichloroacetic acid salt of an NMDA receptor antagonist which is basic or capable of forming a cation. NMDA receptor antagonists which are basic or capable of forming a cation of particular interest are 2-amino-N-(l,2-diphenyl-l-methylethyl)-acetamide, l,2-diphenyl-2- propylamine, (5)-α-phenyl-2-pyridineethanamine), MK-801, N-(3-ethylphenyl)-N-methyl- N'-l-naphthalenyl-guanidine and N-ethyl-l-phenyl-2-(3-pyrazine)ethanamine.
NMDA receptor antagonists which are basic or capable of forming a cation of most particular interest are 2-amino-N-(l,2-diphenyl-l-methylethyl)-acetamide and (S)-a- phenyl-2-pyridineethanamine, especially (5)-α-phenyl-2-pyridineethanamine.
We also provide a dichloroacetic acid salt of an NMDA receptor antagonist which is basic or capable of forming a cation for use as a pharmaceutical.
We also provide a pharmaceutical formulation comprising a dichloroacetic acid salt of an NMDA receptor antagonist which is basic or capable of forming a cation in s admixture with a pharmaceutically acceptable diluent or carrier.
The salt may be made by a metathetical process e.g. by reacting dichloroacetic acid with a suitable salt of the NMDA receptor antagonist. The reaction may be carried out in a solvent which is inert under reaction conditions. The solvent is preferably one in which the desired salt is soluble, e.g. water. The desired salt may be 0 isolated and purified by, for example, crystallisation or freeze drying.
The formulations and salts according to the invention are useful in the treatment of neurodegenerative disorders.
Specific neurodegenerative disorders that may be mentioned include stroke, cerebral ischaemia, cerebral palsy, the effects of hypoglycaemia, epilepsy, AIDS-related s dementia, Alzheimer's disease, Huntington's chorea, Olivo-ponto-cerebellar atrophy, perinatal asphyxia, Parkinson's disease, anoxia, neuronal damage associated with substance abuse (for example, narcotics or cocaine), retinopathies, schizophrenia, ischaemic states after cardiac arrest or surgical operations, intoxication or injuries of the spinal cord and amyotrophic lateral sclerosis. We include within the term o "neurodegenerative disorders" neuronal loss or damage following head injury, brain trauma and sub-arachnoid haemorrhage.
According to the invention there is also provided a pharmaceutical pack comprising: i) DCA, or a pharmaceutically acceptable salt thereof; and 5 ii) an NMDA receptor antagonist; as a combined preparation for simultaneous, separate or sequential administration in the treatment of a neurodegenerative disorder.
By "simultaneous use" is meant administration of the two components in a single pharmaceutical formulation. 0 By "sequential use" is meant administration of the two components in separate pharmaceutical formulations, but with a short period of time between each administration, for example up to 5 minutes.
By "separate use" is meant administration of the two components in separate pharmaceutical formulations, but with a relatively longer period of time between each administration, for example from 5 minutes to 12 hours.
We prefer the administration of the two components to be simultaneous. The components may be administered by any convenient route, for example parenterally, rectally, and orally. Pharmaceutical formulations comprising the components include solid dosage forms, for example tablets, pills, capsules, powders, granules, and suppositories for oral, parenteral or rectal administration; and liquid dosage forms, for example sterile parenteral solutions or suspensions, suitably flavoured syrups, flavoured emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil and peanut oil, and elixirs and similar pharmaceutical diluents or carriers.
Solid compositions may be prepared by mixing the components with pharmaceutical carriers, for example conventional tabletting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate, gums and other diluents, for example water, to form a homogeneous preformulation composition in which the components are uniformly dispersed. The solid dosage forms may be coated or otherwise compounded to prolong the action of the composition.
According to another aspect of this invention there is also provided a method of treatment or prophylaxis of a neurodegenerative disorder, which comprises the simultaneous, separate or sequential administration of: i) DCA, or a pharmaceutically acceptable salt thereof; and ii) an NMDA receptor antagonist; to a patient suffering from or at risk of suffering from such a disorder. We also provide a method of treatment or prophylaxis of a neurodegenerative disorder, which comprises the administration of a dichloroacetic acid salt of an NMDA receptor antagonist which is basic or capable of forming a cation to a patient suffering from or at risk of suffering from such a disorder.
According to another aspect of the invention there is also provided the use of a combination of
(i) DCA, or a pharmaceutically acceptable salt thereof; and
(ii) an NMDA receptor antagonist
in the manufacture of a medicament for simultaneous, separate or sequential administration in the treatment or prophylaxis of a neurodegenerative disorder.
There is also provided the use of a dichloroacetic acid salt of an NMDA receptor antagonist which is basic or capable of forming a cation in the manufacture of s a medicament for the treatment or prophylaxis of a neurodegenerative disorder.
According to another aspect of the invention there is also provided the use of
DCA, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for combination therapy by simultaneous, separate or sequential administration with an NMDA receptor antagonist for the treatment or prophylaxis of 0 a neurodegenerative disorder.
According to another aspect of the invention there is also provided the use of an NMDA receptor antagonist in the manufacture of a medicament for combination therapy by simultaneous, separate or sequential administration with DCA, or a pharmaceutically acceptable salt thereof, for the treatment or prophylaxis of a s neurodegenerative disorder.
For the above-mentioned uses the dosage administered will, of course, vary with the compounds employed, the mode of administration and the treatment desired. However, in general, satisfactory results are obtained when compounds of components (i) and (ii) are each administered at a daily dosage of from about O.lmg to about lOOmg o per kg of body weight, perhaps given in divided doses 1 to 4 times a day or in sustained release form. For man, the total daily dose of DCA is in the range of from 50mg to 5,000mg, more preferably from lOOmg to 3,500mg and for an NMDA antagonist, from 5 mg to l,400mg, more preferably from lOmg to 500mg.
5 Example 1 fSVα-Phenyl-2-pyridineethanamine dihydrochloride
This compound was prepared as described in International Patent Application WO
93/20052.
0 Example 2
Dichloroacetic acid compound with fSVα-phenyl-2-pyridineethanamine t2:!^
To a solution of the free base of the title compound of Example 1 (2.34g, 11.8mmoles) in methanol (10ml) was added dichloroacetic acid (1.5 ml) in methanol (10ml). The
mixture was stirred overnight, and then concentrated to an oil which solidified on standing. The solid was recrystallized from ethyl acetate twice to give the title compound (3.3g). M.p. 110-112°C. [o]D= +34.53° (c= 1.01, CH3OH, 23°C).
Example 3
Solutions of DCA and an NMDA receptor antagonist for intravenous administration to a human patient were prepared as follows:
(a) DCA, 3.5g/l and (S)-α-phenyl-2-pyridineethanamine dihydrochloride, 0.14g/l made up in 1 litre of isotonic saline at pH 7.4.
(b) DCA, 1.75 g/1 and (S)-α-phenyl-2-pyridineethanamine dihydrochloride, 0.07g/l made up in 1 litre of isotonic saline at pH 7.4.
(e) DCA, 3.5g/l and 2-amino-N-(l,2-diphenyl-l-methylethyl)-acetamide, 0.42g/l made up in 1 litre of isotonic saline at pH 7.4. (e) DCA, 3.5g/l and 2-amino-N-(l,2-diphenyl-l-methylethyl)-acetamide, 0.21g/l made up in 1 litre of isotonic saline at pH 7.4.
Claims
1. A pharmaceutical formulation comprising: i) DCA, or a pharmaceutically acceptable salt thereof; and ii) an NMDA receptor antagonist;
5 in admixture with a pharmaceutically acceptable diluent or carrier.
2. A formulation as claimed in claim 1, wherein the NMDA receptor antagonist is2-amino-N-(l,2-diphenyl-l-methylethyl)-acetamide,l,2-diphenyl-2-propylamine,(S)-α- phenyl-2-pyridineethanamine, MK-801, cis-4-[phosphonomethyl]-2-piperidine carboxylic acid, N-(3-ethylphenyl)-N-methyl-N'-l-naphthalenyl-guanidine, N-ethyl-l-phenyl-2-(3- ιo pyrazine)ethanamine or a pharmaceutically acceptable salt of any one thereof.
3. A dichloroacetic acid salt of an NMDA receptor antagonist which is basic or capable of forming a cation.
4. A salt as claimed in claim 3, wherein the NMDA receptor antagonist is 2-amino- N-(l,2-diphenyl-l-methylethyl)-acetamide, l,2-diphenyl-2-propylamine, (5)-α-phenyl-2- i5 pyridineethanamine, MK-801, N-(3-ethylphenyl)-N-methyl-N'-l-naphthalenyl-guanidine or N-ethyl-l-phenyl-2-(3-pyrazine)ethanamine.
5. A salt as claimed in claim 3 or claim 4 for use as a pharmaceutical.
6. A pharmaceutical formulation comprising a salt as claimed in claim 3 or claim 4 in admixture with a pharmaceutically acceptable diluent or carrier.
20 7. A pharmaceutical pack comprising: i) DCA, or a pharmaceutically acceptable salt thereof; and ii) an NMDA receptor antagonist; as a combined preparation for simultaneous, separate or sequential administration in the treatment of a neurodegenerative disorder.
25 8. A pharmaceutical pack according to claim 7, wherein the NMDA receptor antagonist is 2-amino-N-(l,2-diphenyl-l-methylethyl)-acetamide, l,2-diphenyl-2- propylamine, (S)-α-phenyl-2-pyridineethanamine, MK-801, cis-4-[phosphonomethyl]-2- piperidine carboxylic acid, N-(3-ethylphenyl)-N-methyl-N'-l-naphthalenyl-guanidine, N- ethyl-l-phenyl-2-(3-pyrazine)ethanamine or a pharmaceutically acceptable salt of any
30 one thereof.
9. A method of treatment or prophylaxis of a neurodegenerative disorder, which comprises the simultaneous, separate or sequential administration of: i) DCA, or a pharmaceutically acceptable salt thereof; and ii) an NMDA receptor antagonist; to a patient suffering from or at risk of suffering from such a disorder.
10. A method of treatment or prophylaxis according to claim 9 wherein the NMDA receptor antagonist is 2-amino-N-(l,2-diphenyl-l-methylethyl)-acetamide, l,2-diphenyl-2- s propylamine, (5)-α-phenyl-2-pyridineethanamine, MK-801, cis-4-[phosphonomethyl]-2- piperidine carboxylic acid, N-(3-ethylphenyl)-N-methyl-N'-l-naphthalenyl-guanidine, N- ethyl-l-phenyl-2-(3-pyrazine)ethanamine or a pharmaceutically acceptable salt of any one thereof.
11. A method of treatment or prophylaxis of a neurodegenerative disorder, which ιo comprises the administration of a salt as claimed in claim 3 or claim 4 to a patient suffering from or at risk of suffering from such a disorder.
12. The use of a combination of
(i) DCA, or a pharmaceutically acceptable salt thereof; and
(ii) an NMDA receptor antagonist is in the manufacture of a medicament for simultaneous, separate or sequential administration in the treatment or prophylaxis of a neurodegenerative disorder.
13. The use of DCA, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for combination therapy by simultaneous, separate or sequential administration with an NMDA receptor antagonist for the treatment or
20 prophylaxis of a neurodegenerative disorder.
14. The use of an NMDA receptor antagonist in the manufacture of a medicament for combination therapy by simultaneous, separate or sequential administration with DCA, or a pharmaceutically acceptable salt thereof, for the treatment or prophylaxis of a neurodegenerative disorder.
25 15. The use according to any one of claims 12 to 14 wherein the NMDA receptor antagonist is 2-amino-N-(l,2-diphenyl-l-methylethyl)-acetamide, l,2-diphenyl-2- propylamine, (5)-α-phenyl-2-pyridineethanamine, MK-801, cis-4-[phosphonomethyl]-2- piperidiπe carboxylic acid, N-(3-ethylphenyl)-N-methyl-N'-l-naphthalenyl-guanidine, N- ethyl-l-phenyl-2-(3-pyrazine)ethanamine or a pharmaceutically acceptable salt of any
30 one thereof.
16. The use of a salt according to claim 3 or claim 4 in the manufacture of a medicament for the treatment or prophylaxis of a neurodegenerative disorder.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU25347/95A AU2534795A (en) | 1994-05-24 | 1995-05-24 | Combination product of dichloroacetic acid and an nmda antagonist |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9410320A GB9410320D0 (en) | 1994-05-24 | 1994-05-24 | Novel therapeutic method |
GB9410320.7 | 1994-05-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1995031986A1 true WO1995031986A1 (en) | 1995-11-30 |
Family
ID=10755581
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1995/001205 WO1995031986A1 (en) | 1994-05-24 | 1995-05-24 | Combination product of dichloroacetic acid and an nmda antagonist |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU2534795A (en) |
GB (1) | GB9410320D0 (en) |
WO (1) | WO1995031986A1 (en) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004000353A1 (en) * | 2002-06-20 | 2003-12-31 | The Governors Of The University Of Alberta | Dichloroacetate in combination with cardioprotective or hemodynamic drugs |
WO2005077353A1 (en) * | 2004-01-16 | 2005-08-25 | The Governors Of The University Of Alberta | Dichloroacetate in combination with an inotrope for cardioprotection |
EP1908462A2 (en) * | 2002-06-20 | 2008-04-09 | The Governors Of The University Of Alberta | Dichloroacetate in combination with cardioprotective or hemodynamic drugs |
WO2008055945A1 (en) | 2006-11-09 | 2008-05-15 | Probiodrug Ag | 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases |
WO2008065141A1 (en) | 2006-11-30 | 2008-06-05 | Probiodrug Ag | Novel inhibitors of glutaminyl cyclase |
WO2008104580A1 (en) | 2007-03-01 | 2008-09-04 | Probiodrug Ag | New use of glutaminyl cyclase inhibitors |
US7432247B2 (en) | 2002-10-07 | 2008-10-07 | The Governors Of The University Of Alberta | Methods of cardioprotection using dichloroacetate in combination with an inotrope |
US7732162B2 (en) | 2003-05-05 | 2010-06-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases |
WO2011029920A1 (en) | 2009-09-11 | 2011-03-17 | Probiodrug Ag | Heterocylcic derivatives as inhibitors of glutaminyl cyclase |
WO2011107530A2 (en) | 2010-03-03 | 2011-09-09 | Probiodrug Ag | Novel inhibitors |
WO2011110613A1 (en) | 2010-03-10 | 2011-09-15 | Probiodrug Ag | Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5) |
WO2011131748A2 (en) | 2010-04-21 | 2011-10-27 | Probiodrug Ag | Novel inhibitors |
WO2012123563A1 (en) | 2011-03-16 | 2012-09-20 | Probiodrug Ag | Benz imidazole derivatives as inhibitors of glutaminyl cyclase |
EP2865670A1 (en) | 2007-04-18 | 2015-04-29 | Probiodrug AG | Thiourea derivatives as glutaminyl cyclase inhibitors |
EP3461819A1 (en) | 2017-09-29 | 2019-04-03 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4631294A (en) * | 1985-07-05 | 1986-12-23 | University E.M., Inc. | Treatment of cerebral ischemia with dichloroacetate |
EP0356035A2 (en) * | 1988-08-12 | 1990-02-28 | Astra Aktiebolag | Arylkalkyl-amines and -amides having anticonvulsant and neuroprotective properties |
-
1994
- 1994-05-24 GB GB9410320A patent/GB9410320D0/en active Pending
-
1995
- 1995-05-24 WO PCT/GB1995/001205 patent/WO1995031986A1/en active Application Filing
- 1995-05-24 AU AU25347/95A patent/AU2534795A/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4631294A (en) * | 1985-07-05 | 1986-12-23 | University E.M., Inc. | Treatment of cerebral ischemia with dichloroacetate |
EP0356035A2 (en) * | 1988-08-12 | 1990-02-28 | Astra Aktiebolag | Arylkalkyl-amines and -amides having anticonvulsant and neuroprotective properties |
Non-Patent Citations (1)
Title |
---|
CLIN. NEUROPHARMACOL., vol. 13, no. spl.3, pages S9 - S25 * |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1908462A2 (en) * | 2002-06-20 | 2008-04-09 | The Governors Of The University Of Alberta | Dichloroacetate in combination with cardioprotective or hemodynamic drugs |
WO2004000353A1 (en) * | 2002-06-20 | 2003-12-31 | The Governors Of The University Of Alberta | Dichloroacetate in combination with cardioprotective or hemodynamic drugs |
EP1908462A3 (en) * | 2002-06-20 | 2008-06-25 | The Governors Of The University Of Alberta | Dichloroacetate in combination with cardioprotective or hemodynamic drugs |
AU2003278896B2 (en) * | 2002-06-20 | 2009-10-01 | The Governors Of The University Of Alberta | Dichloroacetate in combination with cardioprotective or hemodynamic drugs |
US7432247B2 (en) | 2002-10-07 | 2008-10-07 | The Governors Of The University Of Alberta | Methods of cardioprotection using dichloroacetate in combination with an inotrope |
US7732162B2 (en) | 2003-05-05 | 2010-06-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases |
US8809010B2 (en) | 2003-05-05 | 2014-08-19 | Probiodrug Ag | Method for prophylactic treatment of alzheimer's disease using inhibitors of glutaminyl cyclase and glutamate cyclases |
WO2005077353A1 (en) * | 2004-01-16 | 2005-08-25 | The Governors Of The University Of Alberta | Dichloroacetate in combination with an inotrope for cardioprotection |
WO2008055945A1 (en) | 2006-11-09 | 2008-05-15 | Probiodrug Ag | 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases |
WO2008065141A1 (en) | 2006-11-30 | 2008-06-05 | Probiodrug Ag | Novel inhibitors of glutaminyl cyclase |
EP2481408A2 (en) | 2007-03-01 | 2012-08-01 | Probiodrug AG | New use of glutaminyl cyclase inhibitors |
WO2008104580A1 (en) | 2007-03-01 | 2008-09-04 | Probiodrug Ag | New use of glutaminyl cyclase inhibitors |
EP2865670A1 (en) | 2007-04-18 | 2015-04-29 | Probiodrug AG | Thiourea derivatives as glutaminyl cyclase inhibitors |
WO2011029920A1 (en) | 2009-09-11 | 2011-03-17 | Probiodrug Ag | Heterocylcic derivatives as inhibitors of glutaminyl cyclase |
WO2011107530A2 (en) | 2010-03-03 | 2011-09-09 | Probiodrug Ag | Novel inhibitors |
WO2011110613A1 (en) | 2010-03-10 | 2011-09-15 | Probiodrug Ag | Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5) |
WO2011131748A2 (en) | 2010-04-21 | 2011-10-27 | Probiodrug Ag | Novel inhibitors |
WO2012123563A1 (en) | 2011-03-16 | 2012-09-20 | Probiodrug Ag | Benz imidazole derivatives as inhibitors of glutaminyl cyclase |
EP3461819A1 (en) | 2017-09-29 | 2019-04-03 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
Also Published As
Publication number | Publication date |
---|---|
GB9410320D0 (en) | 1994-07-13 |
AU2534795A (en) | 1995-12-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1995031986A1 (en) | Combination product of dichloroacetic acid and an nmda antagonist | |
EP0230370B1 (en) | Use of specific n-methyl-d-aspartate receptor antagonists in the prevention and treatment of neurodegeneration | |
EP0306060B1 (en) | Pharmaceutical products providing enhanced analgesia | |
CA2317044C (en) | Medicament for neurodegenerative diseases | |
AU717533B2 (en) | Magnesium (-)hydroxycitrate, preparation process, uses and compositions, in particular pharmaceutical compositions, containing it | |
EP2186792B1 (en) | 2-(a-hydroxypentyl) benzoate and its preparation and use | |
EP0193355B1 (en) | Analgesic composition | |
US4452800A (en) | Salts of 3(n-butyl)-4-hydroxy-1-phenyl-1,8-naphthyridine-2(1H)-one and their use in treating chronic obstructive lung diseases | |
EP0874631B1 (en) | Use of valaciclovir for the manufacture of a medicament for the treatment of genital herpes by a single daily application | |
US20090246267A1 (en) | Carnitine Conjugates of Adamantanamines and Neramexane Derivatives as Dual Prodrugs for Various Uses | |
CA2412463A1 (en) | Dextrochlorpheniramine tannate | |
EP0361831B1 (en) | Antiviral nucleoside combination | |
EP0637956B1 (en) | Use of remacemide for the treatment of parkinson's disease | |
HU193845B (en) | Process for preparing synergic pharmaceutical preparations comprising flupyrthine and 4-acetamido-phenol | |
HU192050B (en) | Process for production of medical preparative containing co-dergocrin and one piridin-dicarbonic acid diesthertype calcium-antagonist | |
SK281980B6 (en) | Crystalline (+)l-hydrotartrate, its preparation, pharmaceutical preparation containing it and its use | |
MXPA01005255A (en) | The use of aryl-substituted cyclobutylalkylamines for treating urinary incontinence. | |
US5756550A (en) | Method of treatment of parkinson's disease | |
NL8104527A (en) | NEW PENICILLIN COMPOUND AND PREPARATION MADE THEREOF. | |
EP0504180B1 (en) | Glycyl-p-amino-pyridine for the treatment of senile dementia states | |
IL89351A0 (en) | 4,5,6,7-tetrahydroisothiazolo(4,5-c)pyridines,process for their preparation and pharmaceutical compositions containing them | |
US4006235A (en) | Treating CNS lymphoma | |
US4400384A (en) | 5-o-Cyanobenzyl-4,5,6,7-tetrahydrothieno [3,2-c] pyridine methanesulfonate and other novel salts thereof | |
US4877784A (en) | Histidylprolineamide derivatives | |
US4005203A (en) | Treatment of meningeal leukemia with diamino dichlorophenyl pyrimidine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA FI JP MX NO US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |